Jazz Pharmaceuticals shared a post on LinkedIn:
“News for U.S. media and investors: We’re pleased to announce a pre-clinical research collaboration and option-to-license agreement with AbCellera to discover and develop next-generation T-cell engaging (TCE) multispecific antibodies for GI cancers.
This collaboration leverages AbCellera’s leading antibody discovery and development engine and further diversifies our oncology pipeline-building on our deep experience to help reach more patients with significant unmet need.
We look forward to advancing this work together and unlocking new possibilities in cancer care.
Learn more here.”
Other articles about AbCellera on OncoDaily.